



Wilson Aarhus

2-5 May 2024
Preliminary Program

Program

Thursday May 2

19.00-22.00 Welcome dinner at the venue Comwell, Værkmestergade 2, DK-8000 Aarhus C

Friday May 3

Morning

9.00 Welcome *President, Peter Ott (Aarhus)*

Session I: Important stuff

Chairs:

9.15 Upcoming EASL Guidance: what is new? *Piotr Socha (Warsaw)*

9.35 Discussion *Michael Schilsky (New Haven)*

9.50 Mitochondria in WD: relevance in pathophysiology, diagnosis & monitoring *Eve Roberts (Toronto)*

10.10 How does copper get in and out of the brain? *Svetlana Lutsenko (Baltimore)*

10.30 Coffee break

Session II: Neurologic I

Chairs:

11.00 Markers of neurological damage, can they be used and what about CSF copper? *Oliver Bandmann (Sheffield)*

11.20 Difficulties in the early diagnosis of Wilson Disease *Anna Członkowska (Warsaw)*

11.40 Early neurological worsening in Wilson disease - the current knowledge *Tomasz Litwin (Warsaw)*

12.00 Abstract 1

12.15 Abstract 2

12.30 Lunch

Friday May 3

Afternoon

Session III: Neurologic II*Chairs:*

13.30	Cognitive impairment in Wilson's disease	<i>Samuel Shribman (London)</i>
13.50	Sleep disturbances in Wilson Disease	<i>Valérie Cochen De Cock (Montpellier)</i>
14.05	Functional MRI and other MR modalities to diagnose and understand Wilson Disease	<i>Sule Tinaz (New Haven)</i>
14.25	Disturbances of the olfactory function in Wilson Disease	<i>Jan Bembenek (Warsaw)</i>
14.40	Abstract 3	

Session IV: Poster session

14.55 Poster viewing and coffee break

Session V: Hepatic*Chairs:*

15.55	Mechanisms of Hepatic injury in WD?	<i>Valentina Medici (Sacramento)</i>
16.15	Nuclear receptors in WD	<i>Clavia Ruth Wooton-Kee (Houston)</i>
16.30	Portal hypertension and its prognostic implications in patients with Wilson Disease	<i>Albert Stättermayer (Vienna)</i>
16.45	Metallothionein: a game changer in histopathological diagnosis of Wilson Disease	<i>Uta Merle (Heidelberg)</i>
17.00	Abstract 4	
17.15	End of day	
19.00	Dinner at Smedien, Værkmestergade 7, DK-8000 Aarhus C	

Saturday May 4
Morning

Session VI: Basic science

Chairs:

9.00	Transmembrane copper transport by ATP7B	<i>TBA</i>
9.20	The importance of Autophagy in WD	<i>Roman Polishchuk (Pozzuoli)</i>
9.40	Copper metabolism and possibilities for its regulation	<i>Peep Palumaa (Tallinn)</i>
09.55	Abstract #	
10.10	DNA damage pathways and the contribution of arsenic on copper toxicity in ATP7B ^{-/-} mice	<i>Sanjeev Gupta (Bronx)</i>
10.25	Abstract 5	
10.40	Coffee break	

Session VII: Genetics

Chairs:

11.10	Genotype-phenotype – any news?	<i>Anil Dhawan (London)</i>
11.30	Lessons from genetics after the Spanish National Registry (AEEH)	<i>Luis Garcia Villarreal (Gran Canaria)</i>
11.45	Functional analysis of ATP7B mutations	<i>Nishka Kishore (Toronto)</i>
12.05	Screening for WD using the APT7B protein	<i>Sihoun Hahn (Seattle)</i>
12.25	Abstract 6	
12.40	Lunch	

Saturday May 4

Afternoon

Session VIII: Monitoring
Chairs:

13.40	Rhonda's Story of Wilson Disease	<i>Rhonda Rowland (Atlanta)</i>
14.00	Accurate NCC: A New Biomarker for Wilson Disease	<i>Chris Harrington (Guildford)</i>
14.20	NCC and UCE. Lessons from the Chelate trial	<i>Peter Ott (Aarhus)</i>
14.35	New Data on CuExc from France	<i>TBA</i>
14.50	Abstract #	
15.05	Abstract 7	
15.20	Coffee break	

Session IX: Registries
Chairs:

15.50	TBA	<i>TBA</i>
-------	-----	------------

Several Wilson Disease registries (WD) are now active or being developed: National databases in Poland, France, Spain, England, Austria and Denmark; large local databases, such as in Heidelberg; and newer transnational databases such as the Yale Registry. In this section of the Aarhus Wilson Meeting, we will include a discussion about the registries in WD, the most important data to include, and other key issues related to establishing and maintaining a registry. The session is being prepared by a multinational group.

17.50	End of day	
19.00	Dinner at Havnær, Dagmar Petersens Gade 119, DK-8000 Aarhus C	

Sunday May 5
Morning

Session X: Monitoring

Chairs:

9.00	NCC in ALF	<i>Thomas Sandahl (Aarhus)</i>
9.15	Standardized U-Cu off and on treatment	<i>Isabelle Mohr (Heidelberg)</i>
9.30	Exchangeable copper in a real clinical setting	<i>Zoe Mariño (Barcelona)</i>
9.45	Plasmapheresis in the Management of Fulminant Wilson disease	<i>Seema Alam (New Delhi)</i>
10.00	Abstract 10	
10.15	Coffee break	

Session XI: Upcoming therapies and future perspectives.

Chairs:

10.45	Gene therapy and repair	<i>TBA</i>
11.05	Gene editing in WD	<i>Pasquale Piccolo (Pozzuoli)</i>
11.20	Abstract 11	
11.35	Methanobactin in an animal model of end stage liver disease	<i>Hans Zischka (Neuherberg)</i>
11.55	Future perspectives	<i>TBA</i>
12.10	Closing remarks	<i>Peter Ott (Aarhus)</i>
12.15	Lunch	
13.30	Departure	